Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colorectal Neoplasms × Abituzumab × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Cetuximab 43 Oxaliplatin 38 Irinotecan 38 Fluorouracil 35 Capecitabine 35 Bevacizumab 35 pembrolizumab 34 Leucovorin 33 Nivolumab 21 Gemcitabine 17 regorafenib 13 Panitumumab 12 IFL protocol 12 Cyclophosphamide 12 Folfox protocol 11 Cisplatin 11 Pemetrexed 10 tislelizumab 9 Paclitaxel 9 Carboplatin 9 HMPL-013 8 130-nm albumin-bound paclitaxel 8 durvalumab 7 Specimen Handling 7 Docetaxel 7 trametinib 6 Trifluridine 6 Ipilimumab 6 Drug Therapy 6 trifluridine tipiracil drug combination 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed

232 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡